europe peptide therapeutics Market

The Europe peptide therapeutics market is expected to reach US$ 13,845.87 million by 2027 from US$ 6,988.39 million in 2019; it is estimated to grow at a CAGR of 9.0% from 2020 to 2027. The growth of the Europe peptide therapeutics market is attributed to key driving factors, such as growing investments in peptide therapeutics and increasing prevalence of metabolic disorders and infectious diseases. However, operational limitations of peptides are expected to restrain the growth of the market during the forecast period.

Peptides are naturally occurring biological molecules that play a prominent role in important biological activities. Continuous R&D activities in peptide therapeutics have discovered its benefits in tackling a range of chronic disorders, such as renal disorders, genetic conditions, oncology, and neurodegenerative conditions. Over 7,000 naturally occurring peptides have been identified in recent years, which have crucial roles in human physiology, including actions as neurotransmitters, hormones, ion channel ligands, and growth factors. The effectiveness of the outcomes of peptide therapies is generating investments in the development of new drugs. Also, increasing prevalence of metabolic and infectious diseases is one of the prominent factors expected to drive the peptide therapeutics market. The 9th Edition of the IDF Diabetes Atlas reported that the prevalence of diabetes in Germany had reached 15.3% in 2019. Hence, increase in investments in the development of new drugs for peptide therapies and applicability of therapies for treatment of viral infections and chronic diseases are expected to accelerate the growth of the peptide therapeutics market during the forecast period.

The outbreak of the COVID-19 pandemic has extensively affected the countries in the Europe region. However, growing research on peptide therapies to treat COVID-19 patients is likely to favor the market growth. For instance, a research study, ‘Peptides: Prospects for Use in the Treatment of COVID-19’, was conducted in Russia to study peptides as potential drugs for the complex therapy of COVID-19. Thus, growing research on peptide therapies is expected to positively impact the peptide therapeutics market during the forecast period.

Based on type, the Europe peptide therapeutics market is segmented into generic and innovative. The innovative segment held the largest share of the market in 2019, whereas the generic segment is anticipated to register the highest CAGR in the market during the forecast period.

In terms of route of administration, the Europe peptide therapeutics market is categorized into parenteral, oral, mucosal, pulmonary, and others. The parenteral segment held the largest share of the market in 2019; however, the oral segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on synthesis technology, the Europe peptide therapeutics market is segmented into solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and hybrid technology. The solid phase peptide synthesis segment held the largest share of the market in 2019. The hybrid technology segment is anticipated to register the highest CAGR in the market during the forecast period.

Based on application, the Europe peptide therapeutics market is categorized into cancer, cardiovascular disorder, metabolic disorder, respiratory disorder, pain, and dermatology. The cancer segment held the largest share of the market in 2019. However, the metabolic disorder segment is estimated to register the highest CAGR in the market during the forecast period.

Primary and secondary sources associated with this report on the Europe peptide therapeutics market include Spanish Society of Pharmaceutics and Pharmaceutical Technology (SEFIG), Cancer Research UK (CRUK), and International Agency for Research on Cancer (IARC).